Cessation of Smoking Trial in the Emergency Department: Long-Term Follow-up of a Randomized Controlled Trial
Abstract
Abstract Introduction Emergency departments (EDs) offer a valuable opportunity to deliver smoking cessation interventions. Long-term abstinence confers the maximum health benefits. Methods Adults attending UK EDs who currently smoked were randomized to an intervention (brief advice, e-cigarette, and referral to local stop smoking services) or control (contact details for local stop smoking services). Participants were followed up at 1, 3, and 6 months as part of the main trial. Participants who consented to long-term follow-up were also contacted at approximately 18 months post randomization. For an “all participants” analysis, those who did not consent to long-term follow-up had their smoking status set at the value of the 6-month outcome. Those who did not respond were assumed to be smoking. Results Long-term follow-up occurred between 14 and 22 months, mean = 18 months. Long-term follow-up for those who consented to this was 35% in the intervention group (n = 145) and 34% in the control group (n = 143). For those who consented to long-term follow-up self-reported 7-day abstinence at 18 months was 12.8% in the intervention group (n = 53) and 8.33% in the control group (n = 35) (RR = 1.56, 95% CI = 1.04%−2.32%, p = .031). For all participants self-reported 7-day abstinence at long-term follow-up was 13.8% in the intervention group (n = 67) and 8.6% in the control group (n = 42) (RR = 1.61, 95% CI = 1.12%−2.31%, p = .010). Conclusions Adults who smoke attending the ED who…
How strong is the evidence?
Evidence Hub reads this as a randomized trial, done in people. Its evidence level is 2 of 5 (High · randomized trial). Randomized trials of a reasonable size are the strongest single-study design. Reported size: 145 participants or records.
Read the paper
Related studies
- The Matrisome: In Silico Definition and In Vivo Characterization by Proteomics of Normal and Tumor Extracellular Matrices
- The Escherichia coli MG1655 in silico metabolic genotype: Its definition, characteristics, and capabilities
- In silico pharmacology for drug discovery: methods for virtual ligand screening and profiling
- In silico prediction of splice-altering single nucleotide variants in the human genome
- In silico clinical trials: how computer simulation will transform the biomedical industry
- In silico optimization of a guava antimicrobial peptide enables combinatorial exploration for peptide design
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.